Key result
Combined hormonal contraceptives linked to ~77% higher ischemic stroke risk, lowest with fourth-generation formulations.
Why the study?
Does the use of combined hormonal contraceptives increase the risk of ischemic stroke in nonpregnant women aged 18 to 49 years?
Cohort (n=1,711,757)
Does the use of combined hormonal contraceptives increase the risk of ischemic stroke in nonpregnant women aged 18 to 49 years?
Answers are grounded in this paper and cite their sources.
Use of combined hormonal contraceptives is associated with a 1.77-fold higher incidence of ischemic stroke compared to nonuse, though fourth-generation progestins may carry a lower risk than second-generation formulations.
BACKGROUND: The combined hormonal contraceptive (CHC) with ethinylestradiol and progestins is the most widely used contraceptive method among young women and is used by millions worldwide. However, uncertainties exist about the risk of ischemic stroke associated with the use of CHCs with low-dose ethinylestradiol (<50-µg ethinylestradiol) and with the newest fourth-generation progestins that have only been sparsely investigated for the risk of ischemic stroke. METHODS: In this cohort study based on Danish registries covering the entire Danish female population aged 18 to 49 years from 2004 to 2021, we investigated incidence rate ratios (IRRs) of ischemic stroke using CHCs compared with nonuse of hormonal contraceptives. Analyses focused on comparing CHCs based on ethinylestradiol content (30-40- versus ≤20-μg ethinylestradiol), progestin generation (second, third, and fourth) in CHCs, and route of administration (monophasic versus sequential). Poisson regression models adjusting for age, education, ethnicity, calendar year, and medication used for risk factors were utilized. RESULTS: In total, 1 711 757 nonpregnant women contributed 14 697 788 person-years to the investigation. For users of CHCs containing <50-µg ethinylestradiol, the adjusted IRR was increased by 1.77 (95% CI, 1.62-1.93) compared with nonusers of hormonal contraceptives. IRR did not differ between CHCs with 30- to 40- and ≤20-µg ethinylestradiol. Adjusted incidence rate difference between CHC users and nonusers of hormonal contraceptives ranged from 1 in 100 000 women per year in 18 to 24 years of age to 24 in 100 000 women per year in ≥45 years of age. Incidence rate in users of fourth-generation CHCs was 30% lower than that of second-generation CHCs adjusted IRR (0.70 [95% CI, 0.50-0.98]). IRR for users of third-generation CHCs did not differ significantly from that of second-generation users adjusted IRR (1.14 [95% CI, 0.97-1.35]). CONCLUSIONS: Use of CHCs was associated with a 1.77 higher IRR of ischemic stroke. IRR did not relate to ethinylestradiol content in users of CHCs with <50-µg ethinylestradiol. IRR was 30% lower in users of fourth-generation than in users of second-generation CHCs.
No takes yet. Share an insight, caveat, or question.
Letnar et al. (2024) conducted a cohort in Ischemic stroke (n=1,711,757). Combined hormonal contraceptives (CHCs) vs. Nonuse of hormonal contraceptives was evaluated on Ischemic stroke (IRR 1.77, 95% CI 1.62-1.93). Use of combined hormonal contraceptives was associated with an increased risk of ischemic stroke compared with nonuse, with lower risk in fourth-generation users.
Synapse has enriched 10 related papers. Consider them for comparative context: